biote Corp. (NASDAQ:BTMD) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its holdings in shares of biote Corp. (NASDAQ:BTMD) by 59.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,318 shares of the company’s stock after acquiring an additional 34,999 shares during the period. Bank of New York Mellon Corp owned approximately 0.15% of biote worth $705,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bandera Partners LLC increased its holdings in biote by 7.5% during the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company’s stock valued at $9,054,000 after acquiring an additional 127,410 shares in the last quarter. SW Investment Management LLC raised its position in shares of biote by 3.5% during the 4th quarter. SW Investment Management LLC now owns 675,000 shares of the company’s stock worth $3,334,000 after purchasing an additional 22,651 shares during the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in biote during the 2nd quarter valued at $585,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Insider Buying and Selling at biote

In related news, CFO Robert Charles Peterson sold 11,376 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total value of $86,116.32. Following the completion of the sale, the chief financial officer now directly owns 32,874 shares in the company, valued at approximately $248,856.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 13.90% of the stock is currently owned by corporate insiders.

biote Trading Down 1.3 %

NASDAQ:BTMD opened at $6.03 on Monday. biote Corp. has a 12-month low of $3.65 and a 12-month high of $8.44. The firm has a market cap of $374.08 million, a price-to-earnings ratio of 54.82 and a beta of 0.94. The company’s 50-day moving average is $6.61 and its two-hundred day moving average is $6.42.

biote (NASDAQ:BTMD) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $49.17 million during the quarter, compared to analyst estimates of $50.40 million. biote had a negative return on equity of 20.92% and a net margin of 3.67%. On average, equities research analysts forecast that biote Corp. will post 0.52 earnings per share for the current fiscal year.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.